Evidence map›Paper›PMID 42797465›Full record

ReviewPharmaceuticals (Basel, Switzerland)2026

Current and Emerging Targeted Therapy in Advanced Gastroesophageal Adenocarcinoma.

Oliver Oakley, Umair Mahmood, Yusuf Ahmad, Elizabeth Smyth

Abstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Oliver OakleyDepartment of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LJ, UK.
Umair MahmoodDepartment of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LJ, UK.
Yusuf AhmadHilltops Medical Centre, Kensington Dr, Great Holm, Milton Keynes MK8 9HN, UK.
Elizabeth SmythDepartment of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LJ, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

advanced gastroesophageal adenocarcinomabispecific antibodiesCLDN18.2HER2targeted therapyVEGFR

Identifiers

PMID42797465
PMCPMC13610619

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.